Literature DB >> 20833385

Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results.

Cuei Jyuan Lin1, Hung-Cheng Lai, Kai Hung Wang, Chao Agnes Hsiung, Hwan-Wun Liu, Dah-Ching Ding, Chang-Yao Hsieh, Tang-Yuan Chu.   

Abstract

OBJECTIVE: Management of equivocal Papanicolaou smear result remains to be challenging even with the aid of human papillomavirus test. Recently, 3 novel methylation-silenced genes, PAX1, WT1, and PCDH10, have been found to be specifically associated with cervical cancer. We compared the performances of methylation test of these genes with human papillomavirus tests in triage of equivocal Papanicolaou smear result. STUDY
DESIGN: Two hundred twenty-two women with Papanicolaou smear results of atypical cells of undetermined significance nested to a multicenter, nation-wide cohort (the T1899 cohort) were studied. Status of cervical neoplasm was diagnosed with colposcopic biopsy. Status of gene methylation was determined by methylation-specific polymerase chain reaction. High-risk human papillomavirus DNA was detected by polymerase chain reaction-reverse line blot hybridization and Hybrid Capture 2.
RESULTS: Cervical intraepithelial neoplasm 1, cervical intraepithelial neoplasm 2, cervical intraepithelial neoplasm 3, carcinoma in situ, carcinoma, and normal cervix were diagnosed in 58, 17, 14, 10, 1, and 120 women, respectively. Methylation of PCDH10, WT1, and PAX1 was highly associated with the severity of cervical neoplasm (P < 10⁻⁹, < 10⁻⁷, and < 10⁻⁵, respectively). In comparison with a negative test result, the odds ratio (95% confidence intervals) for cervical intraepithelial neoplasm 3 or more severe neoplasms for women tested positive for methylation of these 3 genes were 26.4 (9.0-77.3), 18.1 (6.9-47.2), and 10.3 (4.1-25.9), respectively; whereas those positive for human papillomavirus polymerase chain reaction and Hybrid Capture 2 were 10.5 (3.5-31.9) and 5.6 (2.3-21.4). In triage for atypical cells of undetermined significance, each methylation test had less colposcopy referral and false-positive rates, but higher false-negative rate than the human papillomavirus tests. With a combination test of PCDH10 or WT1 methylation, a comparable false-negative rate (P = .62) but much less false-positive rate (P = .002) and colposcopy referral rate (P < 10⁻⁶) were achieved.
CONCLUSION: In triage of atypical cells of undetermined significance Papanicolaou smear results, methylation test of WT1 and PCDH10 is superior to human papillomavirus test in this multicenter cohort. Comparing to current human papillomavirus triage, the new test has only one third of false positivity and half of colposcopy referral, with no compromise of the sensitivity in diagnosis of cervical intraepithelial neoplasm 3 or more severe neoplasms. Copyright Â
© 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833385     DOI: 10.1016/j.ajog.2010.07.036

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  16 in total

1.  Long non-coding RNA H19 enhances cell proliferation and anchorage-independent growth of cervical cancer cell lines.

Authors:  Tawin Iempridee
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

Review 2.  Epigenetics and cervical cancer: from pathogenesis to therapy.

Authors:  Jinchuan Fang; Hai Zhang; Sufang Jin
Journal:  Tumour Biol       Date:  2014-02-20

3.  Methylated promoters of genes encoding protocadherins as a new cancer biomarker family.

Authors:  Xinbing Sui; Da Wang; Shumin Geng; Gongli Zhou; Chao He; Xiaotong Hu
Journal:  Mol Biol Rep       Date:  2011-05-21       Impact factor: 2.316

4.  PCDH10 is a candidate tumour suppressor gene in medulloblastoma.

Authors:  Kelsey C Bertrand; Stephen C Mack; Paul A Northcott; Livia Garzia; Adrian Dubuc; Stefan M Pfister; James T Rutka; William A Weiss; Michael D Taylor
Journal:  Childs Nerv Syst       Date:  2011-05-20       Impact factor: 1.475

5.  Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation.

Authors:  Andrew E Teschendorff; Allison Jones; Heidi Fiegl; Alexandra Sargent; Joanna J Zhuang; Henry C Kitchener; Martin Widschwendter
Journal:  Genome Med       Date:  2012-03-27       Impact factor: 11.117

6.  Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control.

Authors:  Hextan Y S Ngan; Suzanne M Garland; Neerja Bhatla; Sonia R Pagliusi; Karen K L Chan; Annie N Y Cheung; Tang-Yuan Chu; Efren J Domingo; You Lin Qiao; Jong Sup Park; Eng Hseon Tay; Wisit Supakarapongkul
Journal:  J Cancer Epidemiol       Date:  2011-04-13

7.  Delta Protocadherin 10 is Regulated by Activity in the Mouse Main Olfactory System.

Authors:  Eric O Williams; Heather M Sickles; Alison L Dooley; Sierra Palumbos; Adam J Bisogni; David M Lin
Journal:  Front Neural Circuits       Date:  2011-08-23       Impact factor: 3.492

8.  Global methylation silencing of clustered proto-cadherin genes in cervical cancer: serving as diagnostic markers comparable to HPV.

Authors:  Kai-Hung Wang; Cuei-Jyuan Lin; Chou-Jen Liu; Dai-Wei Liu; Rui-Lan Huang; Dah-Ching Ding; Ching-Feng Weng; Tang-Yuan Chu
Journal:  Cancer Med       Date:  2014-11-21       Impact factor: 4.452

9.  Comparison of HPV genotyping and methylated ZNF582 as triage for women with equivocal liquid-based cytology results.

Authors:  Yu-Ligh Liou; Yu Zhang; Yingzi Liu; Lanqin Cao; Chong-Zhen Qin; Tao-Lan Zhang; Chi-Feng Chang; Huei-Jen Wang; Shu-Yi Lin; Tang-Yuan Chu; Yi Zhang; Hong-Hao Zhou
Journal:  Clin Epigenetics       Date:  2015-04-28       Impact factor: 6.551

Review 10.  Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and meta-analysis.

Authors:  Hung N Luu; Kristina R Dahlstrom; Patricia Dolan Mullen; Helena M VonVille; Michael E Scheurer
Journal:  Cancer Med       Date:  2013-04-21       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.